eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
6/2018
vol. 14
 
Share:
Share:
more
 
 
abstract:
Clinical research

A novel approach for preventing recurrence of malign pleural effusion: early phase pleurodesis

Ufuk Cobanoglu, Ozgur Kemik, Sebahattin Celik, Fuat Sayir

Arch Med Sci 2018; 14, 6: 1404–1415
Online publish date: 2018/01/04
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The effective control of malignant pleural effusion (MPE) is of paramount importance in the treatment of patients with disseminated cancer. In this study, we compared two different approaches (early pleurodesis versus late pleurodesis) to MPE.

Material and methods
Patients (188 cases) whose primary tumor type was known and who were confirmed to have MPE, were included in the study and were separated into two groups. One group consisted of patients who were asymptomatic and who underwent early phase pleurodesis (group I, n = 79). The other group (group II, n = 109) was composed of patients who were symptomatic and whose pleurodesis was performed later. In all cases, pleural effusion was evaluated by means of direct radiography. Computed tomography was performed with the goal of confirming the parenchymal or mediastinal lesions accompanying the pleural fluid.

Results
The rate of complete success in group I cases was observed to be higher, while the rate of recurrence was lower (p = 0.001 and p = 0.002, respectively) than group II. In multiple logistic regression analysis, co-morbidities and the group that patient belong were found to be significant in terms of pleurodesis success (p = 0.02 and p = 0.03). There was a significant difference in survival time between group I and group II, with group I exhibiting longer average survival time (log rank test p < 0.001).

Conclusions
We observed that the success rate was lower and the rate of recurrence higher in the late pleurodesis group, whose members already had greater volumes of pleural effusion.

keywords:

malignant, pleural effusion, pleurodesis, recurrence

references:
Marel M, Fila L, Červená M. The differential diagnosis of pleural effusions. Vnitr Lek Fall 2016; 62: 598-604.
Psallidas I, Kalomenidis I, Porcel JM, et al. Malignant pleural effusion: from bench to bedside. Eur Respir Rev 2016; 25: 189-98.
Dixit R, Agarwal KC, Gokhroo A, et al. Diagnosis and management options in malignant pleural effusions. Lung India 2017; 34: 160-6.
Nagelkerke NJD. A note on the general definition of the coefficient of determination. Biometrika 1991; 78: 691-2.
Clive, A, Jones, H, Bhatnagar R, et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev 2016; 5: CD010529.
Poyraz N, Kalkan H, Odev K, et al. Imaging of pleural diseases: evaluation of imaging methods based on chest radiography. Tuberk Toraks 2017; 65: 41-55.
Lee YCG, Light RW. Pleural effusion: overview. In: Encyclopedia of Respiratory Diseases. 4th ed. Laurent GJ, Shapiro S (eds). Elsevier, Oxford 2006; 353-8.
Davies HE, Lee YC. Management of malignant pleural effusions: questions that need answers. Curr Opin Pulm Med 2013; 19: 374-9.
Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004; 1: CD002916.
Ferreiro L, Suárez-Antelo J, Valdés L. Pleural procedures in the management of malignant effusions. Ann Thorac Med 2017; 12: 3-10.
Roberts ME, Neville E, Berrisford RG, et al. BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65: 32-40.
Santos PS, Marques MA, Cruz C, et al. Predictors of talc slurry pleurodesis success in patients with malignant pleural effusions. Rev Port Pneumol 2017; 23: 216-20.
Agarwal R, Paul AS, Aggarwal AN, et al. A randomized controlled trial of the efficacy of cosmetic talc compared with iodopovidone for chemical pleurodesis. Respirology 2011; 16: 1064-9.
Rodriguez-Panadero F, Montes-Worboys A. Mechanisms of pleurodesis. Respiration 2012; 83: 91-8.
Steger V, Mika U, Toomes H, et al. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. Ann Thorac Surg 2007; 83: 1940-5.
Hunt BM, Farivar AS, Vallières E, et al. Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions. Ann Thorac Surg 2012; 94: 1053-7.
Fysh ET, Waterer GW, Kendall PA, et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest 2012; 142: 394-400.
Bernard A, de Dompsure RB, Hagry O, et al. Early and late mortality after pleurodesis for malignant pleural effusion. Ann Thorac Surg 2002; 74: 213-7.
Rajwa P, Życzkowski M, Paradysz A, et al. Novel hematological biomarkers predict survival in renal cell carcinoma patients treated with nephrectomy. Arch Med Sci 2017; DOI: https://doi.org/10.5114/aoms.2017.70250.
Spych M, Gottwald L, Klonowicz M, et al. The analysis of prognostic factors affecting post-radiation acute reaction after conformal radiotherapy for non-small cell lung cancer. Arch Med Sci 2010; 5: 756-3.
Law MF, Chan HN, Leung C, et al. Marginal zone B-cell lymphoma mimicking extramedullary plasmacytoma and the clinical outcome after treatment. Arch Med Sci 2017; 13: 698-701.
Szychta P, Westfal B, Maciejczyk R, et al. Intraoperative diagnosis of sentinel lymph node metastases in breast cancer treatment with one-step nucleic acid amplification assay (OSNA). Arch Med Sci 2016; 12: 1239-46.
Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014; 69: 1098-104.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe